Phase 2 N=25 Postmenopausal Women Estrogen and Progesterone Infusion
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
Phase 3 N=1,083 Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
Endometrial Hyperplasia · Osteoporosis
Primary: Percentage of Participants With Hyperplasia at Screening
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 4 N=109 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Bone Loss · Osteoporosis · Breast Cancer
Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change
Phase 2 N=11 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) — 2.0 percent change
Phase 4 N=79 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women
Overweight
Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass
Phase 2 N=42 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
Phase 4 N=24 Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function
Cardiovascular Diseases
Primary: Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD) — 5.49; 3.39 % FMD after 6 weeks of treatment — p=0.04
Phase 2 N=40 Vitamin D in Postmenopausal Women at High Risk for Breast Cancer
Breast Cancer
Primary: Change in Serum 25(OH)D — 25; 33 ng/ml
Phase 1 N=29 A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
Postmenopausal Symptoms
Primary: Immunohistochemistry (IHC) Proliferative Effects Measurement — 0.73; 0.43; 0.25 Square root of % positive stained cells — p=<0.001
Phase 3 N=1,271 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
Hypoactive Sexual Desire Disorder
Primary: Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1…
Phase 3 N=248 Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
Menopause · Osteoporosis · Osteopenia
Primary: Change From Baseline in Bone Mineral Density — 1.146; 1.132 g/cm2
Phase 3 N=200 An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8 — 8.4; 11.2; 11.0; 16.5 percent
N/A N=64 Lactobacillus Acidophilus and Postmenopausal Women
Bone Loss · Post Menopausal Osteoporosis · Mineralization
Primary: Calcium — 1.88; 2.04 mmol/L
Phase 2 N=165 Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 — -0.33; 2.96; 3.47; 4.97 percent change
N/A N=92 Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
Arterial Stiffening · Aging · Menopause
Primary: Arterial Stiffness (Carotid Artery Compliance) During Saline — 1.31; 1.34; 0.90; 1.02 mm2/mm Hg×10-1
Phase 3 N=301 Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
Atrophy · Vaginal Diseases
Primary: Incidence of Adverse Events (AEs) — 220; 67; 34; 13 Participants
N/A N=19 Role of T-cells in Post-Menopausal Osteoporosis
Osteoporosis
Primary: Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells — 3.6; 1.8 percentage of CD3 positive cells
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
Phase 2 N=96 Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Human Immunodeficiency Virus
Primary: Safety of Dapivirine (25 mg) Administered in a Silicone Elastomer Vaginal Matrix Ring in HIV-uninfected Postmenopausal Women, When Inserted Once Every 4 Weeks During 12…
Early Phase 1 N=8 Raising Insulin Sensitivity in Post Menopause
Menopause
Primary: Effect of CE/BZA (TSEC) on Body Composition — 91.3; 90.6; 45.5; 45.7 Kilograms
Phase 2 N=190 Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
Vasomotor Symptoms (VMS)
Primary: Percentage of Subjects With Adverse Events — 56.7 percentage of subjects
Phase 3 N=722 Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
Postmenopausal Vulvovaginal Atrophy
Primary: Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Week 12/Final Visit — 2.49; 2.46; 2.50; 2.50 score on a scale
Phase 3 N=336 Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis
Menopause · Postmenopausal Vaginal Atrophy
Primary: Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies — 0; 0; 0; 0 percentage of participants
Phase 1 N=60 A Study of LY2541546 in Healthy Postmenopausal Women
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 3 N=20 Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
Menopause
Primary: Vaginal Cytokines at Baseline — 2.73; 3.19; 0.12; 0.04 pg/ug protein
Phase 1 N=59 A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 3 N=764 Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
Vulvovaginal Atrophy · Menopause · Dyspareunia
Primary: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells — 17.50; 16.72; 23.20; 5.63 percentage of vaginal superficial cells — p=< 0.0001